Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1993 May;56(5):467–472. doi: 10.1136/jnnp.56.5.467

Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.

H Shinotoh 1, O Inoue 1, K Hirayama 1, A Aotsuka 1, M Asahina 1, T Suhara 1, T Yamazaki 1, Y Tateno 1
PMCID: PMC1015002  PMID: 8505636

Abstract

Striatal dopamine D1 receptors were investigated in 11 patients with Parkinson's disease (PD), five patients with striatonigral degeneration (SND) and six age-matched controls by positron emission tomography and carbon-11 labelled SCH23390. The SND patients showed mean 12%, 21%, and 31% declines in the ratios of radioactivity in the caudate, anterior putamen, and posterior putamen compared with that in the occipital cortex. These ratios were not significantly altered in the PD patients. The results may explain the different therapeutic responses to levadopa between SND and PD patients, and this technique might prove useful for their differentiation.

Full text

PDF
467

Images in this article

469Image
on p.469
469Image
on p.469

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brooks D. J., Ibanez V., Sawle G. V., Playford E. D., Quinn N., Mathias C. J., Lees A. J., Marsden C. D., Bannister R., Frackowiak R. S. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992 Feb;31(2):184–192. doi: 10.1002/ana.410310209. [DOI] [PubMed] [Google Scholar]
  2. Brooks D. J., Ibanez V., Sawle G. V., Quinn N., Lees A. J., Mathias C. J., Bannister R., Marsden C. D., Frackowiak R. S. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990 Oct;28(4):547–555. doi: 10.1002/ana.410280412. [DOI] [PubMed] [Google Scholar]
  3. Cash R., Raisman R., Ploska A., Agid Y. Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease. J Neurochem. 1987 Oct;49(4):1075–1083. doi: 10.1111/j.1471-4159.1987.tb09996.x. [DOI] [PubMed] [Google Scholar]
  4. Cortés R., Camps M., Gueye B., Probst A., Palacios J. M. Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res. 1989 Mar 27;483(1):30–38. doi: 10.1016/0006-8993(89)90031-0. [DOI] [PubMed] [Google Scholar]
  5. Cortés R., Gueye B., Pazos A., Probst A., Palacios J. M. Dopamine receptors in human brain: autoradiographic distribution of D1 sites. Neuroscience. 1989;28(2):263–273. doi: 10.1016/0306-4522(89)90178-4. [DOI] [PubMed] [Google Scholar]
  6. De Volder A. G., Francart J., Laterre C., Dooms G., Bol A., Michel C., Goffinet A. M. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol. 1989 Aug;26(2):239–247. doi: 10.1002/ana.410260210. [DOI] [PubMed] [Google Scholar]
  7. Drayer B. P. Imaging of the aging brain. Part II. Pathologic conditions. Radiology. 1988 Mar;166(3):797–806. doi: 10.1148/radiology.166.3.3277248. [DOI] [PubMed] [Google Scholar]
  8. Duguid J. R., De La Paz R., DeGroot J. Magnetic resonance imaging of the midbrain in Parkinson's disease. Ann Neurol. 1986 Dec;20(6):744–747. doi: 10.1002/ana.410200618. [DOI] [PubMed] [Google Scholar]
  9. Fearnley J. M., Lees A. J. Striatonigral degeneration. A clinicopathological study. Brain. 1990 Dec;113(Pt 6):1823–1842. doi: 10.1093/brain/113.6.1823. [DOI] [PubMed] [Google Scholar]
  10. Godfrey K. Statistics in practice. Comparing the means of several groups. N Engl J Med. 1985 Dec 5;313(23):1450–1456. doi: 10.1056/NEJM198512053132305. [DOI] [PubMed] [Google Scholar]
  11. Graham W. C., Clarke C. E., Boyce S., Sambrook M. A., Crossman A. R., Woodruff G. N. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res. 1990 Apr 23;514(1):103–110. doi: 10.1016/0006-8993(90)90440-m. [DOI] [PubMed] [Google Scholar]
  12. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  13. Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature. 1979 Jan 11;277(5692):93–96. doi: 10.1038/277093a0. [DOI] [PubMed] [Google Scholar]
  14. Pierot L., Desnos C., Blin J., Raisman R., Scherman D., Javoy-Agid F., Ruberg M., Agid Y. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci. 1988 Sep;86(2-3):291–306. doi: 10.1016/0022-510x(88)90106-2. [DOI] [PubMed] [Google Scholar]
  15. Pimoule C., Schoemaker H., Reynolds G. P., Langer S. Z. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol. 1985 Aug 15;114(2):235–237. doi: 10.1016/0014-2999(85)90634-x. [DOI] [PubMed] [Google Scholar]
  16. Quik M., Spokes E. G., Mackay A. V., Bannister R. Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease. J Neurol Sci. 1979 Nov;43(3):429–437. doi: 10.1016/0022-510x(79)90021-2. [DOI] [PubMed] [Google Scholar]
  17. Quinn N., Critchley P., Marsden C. D. Young onset Parkinson's disease. Mov Disord. 1987;2(2):73–91. doi: 10.1002/mds.870020201. [DOI] [PubMed] [Google Scholar]
  18. Quinn N. Multiple system atrophy--the nature of the beast. J Neurol Neurosurg Psychiatry. 1989 Jun;Suppl:78–89. doi: 10.1136/jnnp.52.suppl.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Raisman R., Cash R., Ruberg M., Javoy-Agid F., Agid Y. Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol. 1985 Jul 31;113(3):467–468. doi: 10.1016/0014-2999(85)90101-3. [DOI] [PubMed] [Google Scholar]
  20. Rinne J. O., Laihinen A., Någren K., Bergman J., Solin O., Haaparanta M., Ruotsalainen U., Rinne U. K. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J Neurosci Res. 1990 Dec;27(4):494–499. doi: 10.1002/jnr.490270409. [DOI] [PubMed] [Google Scholar]
  21. Rinne J. O., Rinne J. K., Laakso K., Lönnberg P., Rinne U. K. Dopamine D-1 receptors in the parkinsonian brain. Brain Res. 1985 Dec 16;359(1-2):306–310. doi: 10.1016/0006-8993(85)91441-6. [DOI] [PubMed] [Google Scholar]
  22. Seeman P., Bzowej N. H., Guan H. C., Bergeron C., Reynolds G. P., Bird E. D., Riederer P., Jellinger K., Tourtellotte W. W. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology. 1987 Dec;1(1):5–15. doi: 10.1016/0893-133x(87)90004-2. [DOI] [PubMed] [Google Scholar]
  23. Shimoyama M., Kito S., Itoga E., Kishida T., Nanba K. Binding experiments of muscarinic acetylcholine and dopamine receptors in human brains with emphasis on a case of striatonigral degeneration. Jpn J Pharmacol. 1982 Dec;32(6):1157–1166. doi: 10.1254/jjp.32.1157. [DOI] [PubMed] [Google Scholar]
  24. Stoof J. C., Kebabian J. W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature. 1981 Nov 26;294(5839):366–368. doi: 10.1038/294366a0. [DOI] [PubMed] [Google Scholar]
  25. Suzuki K., Inoue O., Hashimoto K., Yamasaki T., Kuchiki M., Tamate K. Computer-controlled large scale production of high specific activity [11C]RO 15-1788 for PET studies of benzodiazepine receptors. Int J Appl Radiat Isot. 1985 Dec;36(12):971–976. doi: 10.1016/0020-708x(85)90258-3. [DOI] [PubMed] [Google Scholar]
  26. Trugman J. M., Pronsky C. J., Wooten G. F. Basal ganglia dopamine depletion does not alter D1 dopamine receptor binding properties. Adv Neurol. 1990;53:107–110. [PubMed] [Google Scholar]
  27. Walters J. R., Bergstrom D. A., Carlson J. H., Chase T. N., Braun A. R. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science. 1987 May 8;236(4802):719–722. doi: 10.1126/science.2953072. [DOI] [PubMed] [Google Scholar]
  28. Ward C. D., Gibb W. R. Research diagnostic criteria for Parkinson's disease. Adv Neurol. 1990;53:245–249. [PubMed] [Google Scholar]
  29. van Leeuwen R. B., Perquin W. V. Striatonigral degeneration. A case report and a review of the literature. Clin Neurol Neurosurg. 1988;90(2):121–124. doi: 10.1016/s0303-8467(88)80030-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES